Atea Pharmaceuticals (AVIR) Net Cash Flow: 2020-2022
Historic Net Cash Flow for Atea Pharmaceuticals (AVIR) over the last 3 years, with Dec 2022 value amounting to $11.9 million.
- Atea Pharmaceuticals' Net Cash Flow rose 115.86% to $11.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$576.0 million, marking a year-over-year decrease of 573.39%. This contributed to the annual value of -$79.1 million for FY2024, which is 76.48% down from last year.
- As of Q4 2022, Atea Pharmaceuticals' Net Cash Flow stood at $11.9 million, which was up 102.35% from -$508.1 million recorded in Q3 2022.
- In the past 5 years, Atea Pharmaceuticals' Net Cash Flow registered a high of $744.7 million during Q4 2020, and its lowest value of -$508.1 million during Q3 2022.
- For the 3-year period, Atea Pharmaceuticals' Net Cash Flow averaged around $13.9 million, with its median value being -$13.4 million (2020).
- Its Net Cash Flow has fluctuated over the past 5 years, first soared by 324.79% in 2021, then tumbled by 2,271.42% in 2022.
- Quarterly analysis of 3 years shows Atea Pharmaceuticals' Net Cash Flow stood at $744.7 million in 2020, then plummeted by 110.11% to -$75.3 million in 2021, then surged by 115.86% to $11.9 million in 2022.
- Its Net Cash Flow was $11.9 million in Q4 2022, compared to -$508.1 million in Q3 2022 and -$21.1 million in Q2 2022.